Glioblastoma
Pipeline by Development Stage
Drug Modality Breakdown
Oncology is a $53.9B market in consolidation, dominated by a handful of megacap players with blockbuster franchises approaching patent expiration.
Key Trends
- Heavy patent cliff exposure (REVLIMID $3.9B LOE 2028, JAKAFI $1.9B LOE 2028)
- Kinase inhibitors and immunomodulatory agents dominate spend; limited diversification in top 10
- Clinical trial volume remains exceptionally high (29,145 trials) but concentration in Phase 1-2 signals early-stage pipeline challenges
Career Verdict
Strong near-term opportunity for R&D and medical affairs roles, but competitive landscape and patent cliff urgency favor specialists over generalists.
AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data
Market Leaders
| # | Product | Company | Revenue | Share | Stage | Trend | LOE |
|---|---|---|---|---|---|---|---|
| 1 | ELIQUIS (apixaban) | Bristol Myers Squibb | $18.3B | 34% | Launch | Stable | 15.0yr |
| 2 | FARXIGA (dapagliflozin) | AstraZeneca | $4.3B | 8% | Peak | Stable | 15.4yr |
| 3 | REVLIMID (lenalidomide) | Bristol Myers Squibb | $3.9B | 7% | LOE Approaching | Declining | 1.8yr |
| 4 | XTANDI (enzalutamide) | Astellas | $2.6B | 5% | Peak | Stable | 10.7yr |
| 5 | IMBRUVICA (ibrutinib) | AbbVie | $2.4B | 4% | Peak | Stable | 8.9yr |
Drug Class Breakdown
concentrated in single product
single dominant product
multi-product class, competitive
facing near-term patent cliff
prostate cancer specialty
niche hematologic oncology
near-term LOE exposure
Career Outlook
StableOncology remains a premium therapeutic area but faces structural headwinds: top 10 products account for >80% of spend, patent cliffs loom (REVLIMID 2028), and late-stage pipeline thinness suggests slower near-term growth. However, high trial volume and consolidation create demand for specialized expertise in regulatory, clinical operations, and lifecycle management. Pharma professionals with kinase inhibitor, immunomodulatory, or ADC experience are in highest demand.
Breaking In
Entry-level candidates should target CROs (Thermo Fisher, IQVIA), emerging biotech (BeiGene, BeOne), or contract manufacturing; oncology specialization requires demonstrated domain knowledge.
For Experienced Professionals
Experienced professionals should focus on lifecycle/patent strategy roles (high salary, low headcount) or pivot to emerging modalities (ADCs, bispecifics) to avoid commoditization in crowded kinase inhibitor space.
In-Demand Skills
Best For
Hiring Landscape
Oncology hiring is actively concentrated at Thermo Fisher Scientific (CRO/CDMO services, 559 jobs), AstraZeneca (208 jobs), and emerging biotech players like BeiGene (185 jobs). Commercial roles dominate (412 jobs, $136K avg) but R&D positions offer the highest salary premium ($199K avg, 347 roles). Patent cliff urgency is creating acute demand for regulatory, CMC, and lifecycle management expertise.
Top Hiring Companies
By Department
Strong near-term hiring momentum, especially in CRO/CDMO and emerging biotech; Medical Affairs offers highest compensation but limited headcount.
On Market (2)
Approved therapies currently available
Competitive Landscape
99 companies ranked by most advanced pipeline stage
+69 more companies
Trial Timeline
Clinical trial activity over time
Showing 15 of 50 trials with date data
Clinical Trials (50)
Total enrollment: 9,496 patients across 50 trials
Standard Temodal (Temozolomide) Regimen Versus Standard Regimen Plus Early Postsurgery Temodal for Newly Diagnosed Glioblastoma Multiforme (Study P05572)
Beginning Radiation Immediately With GammaTile at GBM Excision Versus Standard of Care
EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma
A Study Comparing Niraparib With Temozolomide in Adult Participants With Newly-diagnosed, MGMT Unmethylated Glioblastoma
Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM
Tofacitinib in Recurrent GBM Patients
Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma
Clinical Trial to Assess the Efficacy and Safety of 'Immuncell-LC' With Temozolomide in Newly Diagnosed Glioblastoma of Korea
Enzastaurin Versus Lomustine in Glioblastoma
Efficacy and Safety of Temodal vs Semustine in Subjects With Recurrent Glioblastoma or Anaplastic Astrocytoma (Study P03644)
Phase III Trial of Primary Radio- or Chemotherapy in Malignant Astrocytoma of the Elderly
Study of IV Edotecarin Vs Temozolomide or Carmustine (BCNU) or Lomustine (CCNU) in Patients With Glioblastoma Multiforme
A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
Adjuvant Temozolomide ± 5-Aminolevulinic Acid + Low Intensity Diffuse Ultrasound Sonodynamic Therapy System for Newly Diagnosed Glioblastoma
Ruxolitinib With Radiation and Temozolomide Compared to Radiation and Temozolomide for Newly Diagnosed Glioblastoma
N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma
A Study With L19TNF in Combination With Lomustine in Patients With Glioblastoma at Progression or Recurrence
Azeliragon in MGMT Unmethylated Glioblastoma
A Phase 2b Clinical Study With a Combination Immunotherapy in Newly Diagnosed Patients With Glioblastoma
ARISTOCRAT: Blinded Trial of Temozolomide +/- Cannabinoids
Surgical Pembro +/- Olaparib w TMZ for rGBM
Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations
Paxalisib With a High Fat, Low Carb Diet and Metformin for Glioblastoma
Dose Finding for Intraoperative Photodynamic Therapy of Glioblastoma
MBM-02 (Tempol) for the Treatment of Glioblastoma Multiforme (GBM)
Preventive Dendritic Cell Vaccine, AV-COVID-19, in Subjects Not Actively Infected With COVID-19
Neoadjuvant PD-1 in Newly Diagnosed Glioblastoma
DC Migration Study to Evaluate TReg Depletion In GBM Patients With and Without Varlilumab
Anti-GITR/Anti-PD1/Stereotactic Radiosurgery, in Recurrent Glioblastoma
Study of Ad-RTS-hIL-12 + Veledimex in Combination With Cemiplimab in Subjects With Recurrent or Progressive Glioblastoma
Pembrolizumab and Reirradiation in Bevacizumab Naïve and Bevacizumab Resistant Recurrent Glioblastoma
Ferumoxytol MRI in Assessing Response to Pembrolizumab in Patients With Glioblastoma
Convection-Enhanced Delivery (CED) of MDNA55 in Adults With Recurrent or Progressive Glioblastoma
INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)
A Study of Abemaciclib in Recurrent Glioblastoma
Autologuos Lymphoid Effector Cells Specific Against Tumour (ALECSAT) as Add on to Standard of Care in Patients With Glioblastoma
Oral ONC201 in Adult Recurrent Glioblastoma
Study Evaluating the Efficacy and Safety of Selinexor (KPT-330) in Participants With Recurrent Gliomas
Phase 2 Study to Investigate the Efficacy and Safety of Aldoxorubicin in Subjects With Glioblastoma
ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma Multiforme
Imaging Trial With I-124-CLR1404 in Patients With Newly Diagnosed or Recurrent Glioblastoma
BIBF 1120 for Recurrent High-Grade Gliomas
A Study in Recurrent Glioblastoma (GB)
Safety and Efficacy of PF-299804 (Dacomitinib), a Pan-HER Irreversible Inhibitor, in Patients With Recurrent Glioblastoma With EGFR Amplification or Presence of EGFRvIII Mutation. A Phase II CT.
A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma
Phase II Study of BKM120 for Subjects With Recurrent Glioblastoma
Bosutinib in Adult Patients With Recurrent Glioblastoma
A Trial Of PF-04856884 In Patients With Recurrent Glioblastoma
A Study of PD 0332991 in Patients With Recurrent Rb Positive Glioblastoma
PF-00299804 in Adult Patients With Relapsed/Recurrent Glioblastoma
Related Jobs in Oncology
DMPK Scientist
Clinical Oncology Specialist
Director Group Patents
Territory Manager- Flanders
Security Governance Specialist
Document Controller
Phase Legend
Key Insights
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.